Aprea Therapeutics, a privately held, clinical stage biopharmaceutical company developing novel anticancer therapies targeting the tumor suppressor protein p53, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to...
Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reports positive results for the secondary endpoints of its Phase III clinical trial evaluating the safety and efficacy of conventional...
The GAIN Trial will assess whether a new investigational medicine targeting P. gingivalis bacteria can slow or halt progression of Alzheimer’s disease Researchers seek more than 500 participants in the United States and Europe; visit www.GAINtrial.com for information...
Data to be presented today at 2019 Muscular Dystrophy Association Clinical and Scientific Conference Phase 2/3 clinical trial for suvodirsen in DMD expected to initiate in July 2019 Interim efficacy data from ongoing open-label extension study expected in H2 2019...
Circuit Clinical™ is proud to announce a unique collaboration with Roswell Park Comprehensive Cancer Center, to support the expansion of clinical trial opportunities to its outpatient oncology practices. This collaboration marks Circuit Clinical’s entry into...
–Top-Line Results Show High Rates of Participant Compliance and Satisfaction and Excellent Data Integrity with Home-Based Clinical Data Capture Using Transparency Virtual TrialsTM (TVT) Platform– –TVT Integrates Telemedicine, Mobile Health and Cloud...
Email
Text